A New Chapter in Prostate Cancer Care: First Patients Dosed in Pivotal OPTIMAL-E Trial iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation BioNTech Navigates Shifting Tides: Q1 2026 Showcases Pipeline Progress Amidst Revenue Recalibration